Invesco Nasdaq Biotechnology ETF(IBBQ.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Invesco Nasdaq Biotechnology ETF
IBBQ.US
News
View More

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received a consensus recommendation of "Moderate Buy" from 27 analysts. The average 1-year target price is $490.96, with 22 buy ratings, 4 hold ratings, and 1 sell rating. Recent analyst updates include price target adjustments from various firms, with Barclays raising their target to $527. Negative sentiment arose from Bank of America's pessimistic forecast and insider stock sales, leading to a 9% drop in stock price after the 2030 plan reveal. Insiders sold 56,955 shares in the last 90 days, reducing their ownership by 1.50%.

Market Beat·
US
ALNY
0.00%
Market Beat·
US
ALNY
0.00%

Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell-Off

Several top executives at Alnylam Pharmaceuticals, including CEO Yvonne Greenstreet, have sold significant amounts of company stock in a synchronized sell-off, totaling over $6 million. This insider selling comes amid renewed analyst attention from Oppenheimer, which initiated coverage with a positive outlook on the company's drug Amvuttra, despite concerns about market pressures. Spark's AI Analyst rates ALNY as Neutral, citing strong earnings but high valuation concerns. Alnylam's stock has seen a year-to-date decline of 6.96% with a current market cap of $49 billion.

Tip Ranks·
US
ALNY
0.00%
Tip Ranks·
US
ALNY
0.00%

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Amgen Inc. reported positive results for its obesity drug MariTide, showing sustained weight loss for a second year with fewer doses and good safety. At the J.P. Morgan Healthcare Conference, CEO Robert Bradway highlighted that most participants maintained weight loss on lower doses, with low side effects. Analysts see potential for MariTide to capture significant market share and project multibillion-dollar sales. Amgen's stock rose 0.46% to $325.80 following the announcement.

benzinga_article·
US
AMGN
+0.12%
benzinga_article·
US
AMGN
+0.12%

AZ's $80B revenue target 'very much within reach,' CFO says

AstraZeneca's CFO Aradhana Sarin stated at the J.P. Morgan Healthcare Conference that the company's $80 billion revenue target for 2030 is achievable, especially if they maintain last year's success in phase 3 trials. The oncology portfolio has seen significant growth, with 10 positive phase 3 readouts last year and an increase in late-stage drug opportunities. Analysts' projections for 2030 have risen to match the target. Key products include Imfinzi and Tagrisso, with ongoing trials expected to enhance their market positions. AstraZeneca is also focusing on cardiovascular drugs and navigating drug pricing regulations.

Fiercepharma·
US
AZN
+0.43%
Fiercepharma·
US
AZN
+0.43%

Argenx receives review from FDA for VYVGART in seronegative gMG

Argenx announced that the FDA has accepted for priority review its supplemental biologics license application for VYVGART, aimed at treating adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis (gMG). The target action date is set for May 10, 2026. Chief Medical Officer Luc Truyen emphasized the need for improved treatment options for these patients. The application is backed by positive results from the phase 3 ADAPT SERON study, which demonstrated significant improvements in daily living activities for patients treated with VYVGART, with a favorable safety profile.

PharmaTimes·
US
ARGX
-1.63%
PharmaTimes·
US
ARGX
-1.63%
© 2026 Longbridge｜Disclaimer